Related Experiment Videos
Comparison of two injection techniques using botulinum toxin in spastic hemiplegia
M K Childers1, M Stacy, D L Cooke
1Department of Physical Medicine and Rehabilitation, University of Missouri-Columbia, 65212, USA.
American Journal of Physical Medicine & Rehabilitation
|November 1, 1996
Summary
Botulinum toxin type A (BTX-A) injections in the gastrocnemius muscle did not show superior results when injected in the mid-belly versus the origin for spastic hemiplegic gait. Further research on precise injection localization is recommended.
Area of Science:
- Neurology
- Rehabilitation Medicine
- Biomedical Engineering
Background:
- Spastic hemiplegic gait is a common sequela of neurological injury, impacting mobility and quality of life.
- Botulinum toxin type A (BTX-A) is utilized to manage focal spasticity, but optimal injection site selection remains debated.
- Gastrocnemius spasticity frequently contributes to gait abnormalities in hemiplegic patients.
Purpose of the Study:
- To compare the clinical efficacy of BTX-A injections in the mid-belly versus the origin of the gastrocnemius muscle for treating spastic hemiplegic gait.
- To evaluate the impact of injection site on functional outcomes in adults with chronic spastic hemiplegia.
Main Methods:
- A randomized, double-blind, placebo-controlled study involving 17 adult subjects with chronic spastic hemiplegic gait.
- Subjects received 50 units of BTX-A injected either proximally (near origin) or distally (mid-belly) in the gastrocnemius muscle.
- Outcome measures included the Fugl-Meyer score, Ashworth scale, ankle range of motion, and a 50-ft timed walk.
Main Results:
- No significant differences were observed in any outcome measures between the proximal and distal BTX-A injection groups.
- Confounding factors such as concurrent physical therapy and variable duration of illness may have influenced results.
- The study failed to support the hypothesis that mid-belly injections yield superior functional improvements compared to origin injections.
Conclusions:
- The location of BTX-A injections in the gastrocnemius muscle (mid-belly vs. origin) did not significantly affect clinical outcomes for spastic hemiplegic gait in this cohort.
- Further investigation into precise localization techniques, potentially including electromyographic guidance, is warranted to optimize BTX-A treatment for spasticity.
- Current localization methods may not be sufficient to differentiate functional benefits based on injection site in the gastrocnemius muscle.